nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—KCNH2—purkinje fiber—dilated cardiomyopathy	0.062	0.333	CbGeAlD
Ziprasidone—KCNH2—endocardium—dilated cardiomyopathy	0.032	0.172	CbGeAlD
Ziprasidone—Hypochloraemia—Furosemide—dilated cardiomyopathy	0.0178	0.0411	CcSEcCtD
Ziprasidone—Drug fever—Spironolactone—dilated cardiomyopathy	0.0151	0.035	CcSEcCtD
Ziprasidone—HTR7—pulmonary artery—dilated cardiomyopathy	0.0139	0.0746	CbGeAlD
Ziprasidone—Glucose tolerance decreased—Furosemide—dilated cardiomyopathy	0.0137	0.0316	CcSEcCtD
Ziprasidone—HTR7—sympathetic nervous system—dilated cardiomyopathy	0.0135	0.0726	CbGeAlD
Ziprasidone—Hypoglycemic reaction—Lisinopril—dilated cardiomyopathy	0.0113	0.0261	CcSEcCtD
Ziprasidone—Polydipsia—Furosemide—dilated cardiomyopathy	0.00886	0.0205	CcSEcCtD
Ziprasidone—HTR2A—pulmonary artery—dilated cardiomyopathy	0.00866	0.0465	CbGeAlD
Ziprasidone—HTR2A—sympathetic nervous system—dilated cardiomyopathy	0.00842	0.0453	CbGeAlD
Ziprasidone—Hypersomnia—Lisinopril—dilated cardiomyopathy	0.0079	0.0183	CcSEcCtD
Ziprasidone—Diabetic—Lisinopril—dilated cardiomyopathy	0.00618	0.0143	CcSEcCtD
Ziprasidone—DRD4—heart—dilated cardiomyopathy	0.00603	0.0324	CbGeAlD
Ziprasidone—Amenorrhoea—Spironolactone—dilated cardiomyopathy	0.00575	0.0133	CcSEcCtD
Ziprasidone—Flank pain—Lisinopril—dilated cardiomyopathy	0.00512	0.0118	CcSEcCtD
Ziprasidone—Hyperkalaemia—Spironolactone—dilated cardiomyopathy	0.00496	0.0115	CcSEcCtD
Ziprasidone—H1F0—cardiac ventricle—dilated cardiomyopathy	0.00468	0.0251	CbGeAlD
Ziprasidone—Gynaecomastia—Spironolactone—dilated cardiomyopathy	0.00452	0.0104	CcSEcCtD
Ziprasidone—H1F0—myocardium—dilated cardiomyopathy	0.0044	0.0237	CbGeAlD
Ziprasidone—Hypomagnesaemia—Furosemide—dilated cardiomyopathy	0.00432	0.01	CcSEcCtD
Ziprasidone—Renal failure acute—Spironolactone—dilated cardiomyopathy	0.00397	0.00918	CcSEcCtD
Ziprasidone—Flat affect—Furosemide—dilated cardiomyopathy	0.00381	0.00881	CcSEcCtD
Ziprasidone—Lethargy—Spironolactone—dilated cardiomyopathy	0.00374	0.00865	CcSEcCtD
Ziprasidone—Ataxia—Spironolactone—dilated cardiomyopathy	0.00345	0.00797	CcSEcCtD
Ziprasidone—Glycosuria—Furosemide—dilated cardiomyopathy	0.00339	0.00784	CcSEcCtD
Ziprasidone—Injection site pain—Furosemide—dilated cardiomyopathy	0.00337	0.00778	CcSEcCtD
Ziprasidone—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.0033	0.00763	CcSEcCtD
Ziprasidone—Psoriasis—Lisinopril—dilated cardiomyopathy	0.00328	0.00758	CcSEcCtD
Ziprasidone—Gastritis—Spironolactone—dilated cardiomyopathy	0.00324	0.0075	CcSEcCtD
Ziprasidone—Disturbance in attention—Furosemide—dilated cardiomyopathy	0.00317	0.00733	CcSEcCtD
Ziprasidone—Eosinophilia—Spironolactone—dilated cardiomyopathy	0.00314	0.00725	CcSEcCtD
Ziprasidone—Jaundice cholestatic—Furosemide—dilated cardiomyopathy	0.00313	0.00723	CcSEcCtD
Ziprasidone—H1F0—heart—dilated cardiomyopathy	0.00307	0.0165	CbGeAlD
Ziprasidone—Hypocalcaemia—Furosemide—dilated cardiomyopathy	0.003	0.00694	CcSEcCtD
Ziprasidone—Drug interaction—Furosemide—dilated cardiomyopathy	0.00296	0.00685	CcSEcCtD
Ziprasidone—Hyperuricaemia—Furosemide—dilated cardiomyopathy	0.00296	0.00685	CcSEcCtD
Ziprasidone—Gout—Furosemide—dilated cardiomyopathy	0.00294	0.0068	CcSEcCtD
Ziprasidone—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00292	0.00674	CcSEcCtD
Ziprasidone—Hyperlipidaemia—Lisinopril—dilated cardiomyopathy	0.00286	0.00661	CcSEcCtD
Ziprasidone—Throat sore—Lisinopril—dilated cardiomyopathy	0.00286	0.00661	CcSEcCtD
Ziprasidone—Oropharyngeal discomfort—Lisinopril—dilated cardiomyopathy	0.00283	0.00655	CcSEcCtD
Ziprasidone—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.0028	0.00647	CcSEcCtD
Ziprasidone—Haemoptysis—Lisinopril—dilated cardiomyopathy	0.00278	0.00644	CcSEcCtD
Ziprasidone—Renal failure—Spironolactone—dilated cardiomyopathy	0.00278	0.00642	CcSEcCtD
Ziprasidone—KCNH2—cardiac ventricle—dilated cardiomyopathy	0.00269	0.0145	CbGeAlD
Ziprasidone—ADRA2C—cardiac ventricle—dilated cardiomyopathy	0.00265	0.0143	CbGeAlD
Ziprasidone—H1F0—cardiac atrium—dilated cardiomyopathy	0.00263	0.0141	CbGeAlD
Ziprasidone—KCNH2—myocardium—dilated cardiomyopathy	0.00253	0.0136	CbGeAlD
Ziprasidone—ADRA2C—myocardium—dilated cardiomyopathy	0.0025	0.0134	CbGeAlD
Ziprasidone—Urine output increased—Furosemide—dilated cardiomyopathy	0.00248	0.00574	CcSEcCtD
Ziprasidone—Lightheadedness—Furosemide—dilated cardiomyopathy	0.00246	0.00568	CcSEcCtD
Ziprasidone—CHRM2—heart—dilated cardiomyopathy	0.00245	0.0131	CbGeAlD
Ziprasidone—Jaundice cholestatic—Lisinopril—dilated cardiomyopathy	0.00235	0.00542	CcSEcCtD
Ziprasidone—Accidental injury—Lisinopril—dilated cardiomyopathy	0.00233	0.00538	CcSEcCtD
Ziprasidone—Thrombophlebitis—Furosemide—dilated cardiomyopathy	0.0023	0.00532	CcSEcCtD
Ziprasidone—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00229	0.0053	CcSEcCtD
Ziprasidone—Polyuria—Furosemide—dilated cardiomyopathy	0.00227	0.00525	CcSEcCtD
Ziprasidone—Arthropathy—Lisinopril—dilated cardiomyopathy	0.00227	0.00524	CcSEcCtD
Ziprasidone—Oropharyngeal pain—Lisinopril—dilated cardiomyopathy	0.00227	0.00524	CcSEcCtD
Ziprasidone—Cough increased—Lisinopril—dilated cardiomyopathy	0.00225	0.0052	CcSEcCtD
Ziprasidone—Alopecia—Spironolactone—dilated cardiomyopathy	0.00224	0.00518	CcSEcCtD
Ziprasidone—Oliguria—Lisinopril—dilated cardiomyopathy	0.00224	0.00517	CcSEcCtD
Ziprasidone—Drug interaction—Lisinopril—dilated cardiomyopathy	0.00222	0.00514	CcSEcCtD
Ziprasidone—Gout—Lisinopril—dilated cardiomyopathy	0.00221	0.0051	CcSEcCtD
Ziprasidone—Leukocytosis—Lisinopril—dilated cardiomyopathy	0.00219	0.00507	CcSEcCtD
Ziprasidone—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.00217	0.00501	CcSEcCtD
Ziprasidone—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00212	0.00491	CcSEcCtD
Ziprasidone—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.00211	0.00489	CcSEcCtD
Ziprasidone—Thirst—Furosemide—dilated cardiomyopathy	0.0021	0.00484	CcSEcCtD
Ziprasidone—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.00209	0.00482	CcSEcCtD
Ziprasidone—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.00206	0.00476	CcSEcCtD
Ziprasidone—Lethargy—Furosemide—dilated cardiomyopathy	0.00204	0.0047	CcSEcCtD
Ziprasidone—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.00203	0.00468	CcSEcCtD
Ziprasidone—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.002	0.00463	CcSEcCtD
Ziprasidone—Salivary hypersecretion—Lisinopril—dilated cardiomyopathy	0.002	0.00463	CcSEcCtD
Ziprasidone—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00198	0.00457	CcSEcCtD
Ziprasidone—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.00195	0.0045	CcSEcCtD
Ziprasidone—Neuropathy—Lisinopril—dilated cardiomyopathy	0.00194	0.00447	CcSEcCtD
Ziprasidone—Photophobia—Lisinopril—dilated cardiomyopathy	0.00194	0.00447	CcSEcCtD
Ziprasidone—Urinary retention—Furosemide—dilated cardiomyopathy	0.0019	0.00438	CcSEcCtD
Ziprasidone—HTR7—heart—dilated cardiomyopathy	0.0019	0.0102	CbGeAlD
Ziprasidone—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00187	0.00432	CcSEcCtD
Ziprasidone—Dehydration—Furosemide—dilated cardiomyopathy	0.00185	0.00429	CcSEcCtD
Ziprasidone—Lightheadedness—Lisinopril—dilated cardiomyopathy	0.00184	0.00426	CcSEcCtD
Ziprasidone—ADRA1A—heart—dilated cardiomyopathy	0.00183	0.00983	CbGeAlD
Ziprasidone—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00182	0.00421	CcSEcCtD
Ziprasidone—Confusional state—Spironolactone—dilated cardiomyopathy	0.00182	0.0042	CcSEcCtD
Ziprasidone—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00181	0.0042	CcSEcCtD
Ziprasidone—Hypertonia—Lisinopril—dilated cardiomyopathy	0.00181	0.00418	CcSEcCtD
Ziprasidone—Cramp muscle—Furosemide—dilated cardiomyopathy	0.0018	0.00415	CcSEcCtD
Ziprasidone—KCNH2—heart—dilated cardiomyopathy	0.00177	0.00949	CbGeAlD
Ziprasidone—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00176	0.00408	CcSEcCtD
Ziprasidone—ADRA2C—heart—dilated cardiomyopathy	0.00174	0.00936	CbGeAlD
Ziprasidone—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00172	0.00398	CcSEcCtD
Ziprasidone—Eosinophilia—Furosemide—dilated cardiomyopathy	0.00171	0.00394	CcSEcCtD
Ziprasidone—Eczema—Lisinopril—dilated cardiomyopathy	0.00167	0.00385	CcSEcCtD
Ziprasidone—Injury—Lisinopril—dilated cardiomyopathy	0.00163	0.00376	CcSEcCtD
Ziprasidone—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.00162	0.00375	CcSEcCtD
Ziprasidone—Somnolence—Spironolactone—dilated cardiomyopathy	0.0016	0.0037	CcSEcCtD
Ziprasidone—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.00158	0.00365	CcSEcCtD
Ziprasidone—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00157	0.00364	CcSEcCtD
Ziprasidone—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00157	0.00363	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00156	0.0036	CcSEcCtD
Ziprasidone—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00155	0.00359	CcSEcCtD
Ziprasidone—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00153	0.00354	CcSEcCtD
Ziprasidone—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00153	0.00353	CcSEcCtD
Ziprasidone—Renal failure—Furosemide—dilated cardiomyopathy	0.00151	0.00349	CcSEcCtD
Ziprasidone—KCNH2—cardiac atrium—dilated cardiomyopathy	0.00151	0.00812	CbGeAlD
Ziprasidone—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.0015	0.00347	CcSEcCtD
Ziprasidone—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.0015	0.00346	CcSEcCtD
Ziprasidone—Diplopia—Lisinopril—dilated cardiomyopathy	0.0015	0.00346	CcSEcCtD
Ziprasidone—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.0015	0.00346	CcSEcCtD
Ziprasidone—ADRA2C—cardiac atrium—dilated cardiomyopathy	0.00149	0.00801	CbGeAlD
Ziprasidone—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00148	0.00343	CcSEcCtD
Ziprasidone—Sweating—Furosemide—dilated cardiomyopathy	0.00147	0.00341	CcSEcCtD
Ziprasidone—Face oedema—Lisinopril—dilated cardiomyopathy	0.00144	0.00334	CcSEcCtD
Ziprasidone—Urticaria—Spironolactone—dilated cardiomyopathy	0.00143	0.00331	CcSEcCtD
Ziprasidone—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00142	0.00329	CcSEcCtD
Ziprasidone—Ataxia—Lisinopril—dilated cardiomyopathy	0.00141	0.00325	CcSEcCtD
Ziprasidone—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.0014	0.00324	CcSEcCtD
Ziprasidone—Dehydration—Lisinopril—dilated cardiomyopathy	0.00139	0.00322	CcSEcCtD
Ziprasidone—ADRA2A—heart—dilated cardiomyopathy	0.00139	0.00747	CbGeAlD
Ziprasidone—Aripiprazole—ADRB1—dilated cardiomyopathy	0.00138	1	CrCbGaD
Ziprasidone—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00137	0.00316	CcSEcCtD
Ziprasidone—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00136	0.00315	CcSEcCtD
Ziprasidone—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00135	0.00313	CcSEcCtD
Ziprasidone—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00135	0.00313	CcSEcCtD
Ziprasidone—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.00135	0.00311	CcSEcCtD
Ziprasidone—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00134	0.00309	CcSEcCtD
Ziprasidone—Visual impairment—Furosemide—dilated cardiomyopathy	0.00133	0.00307	CcSEcCtD
Ziprasidone—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00133	0.00307	CcSEcCtD
Ziprasidone—Gastritis—Lisinopril—dilated cardiomyopathy	0.00132	0.00306	CcSEcCtD
Ziprasidone—Influenza—Lisinopril—dilated cardiomyopathy	0.00129	0.00299	CcSEcCtD
Ziprasidone—Eye disorder—Furosemide—dilated cardiomyopathy	0.00129	0.00298	CcSEcCtD
Ziprasidone—Tinnitus—Furosemide—dilated cardiomyopathy	0.00129	0.00297	CcSEcCtD
Ziprasidone—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.00128	0.00296	CcSEcCtD
Ziprasidone—Sweating increased—Lisinopril—dilated cardiomyopathy	0.00126	0.00291	CcSEcCtD
Ziprasidone—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00126	0.00291	CcSEcCtD
Ziprasidone—Angiopathy—Furosemide—dilated cardiomyopathy	0.00125	0.00289	CcSEcCtD
Ziprasidone—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00125	0.00288	CcSEcCtD
Ziprasidone—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00123	0.00285	CcSEcCtD
Ziprasidone—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00123	0.00285	CcSEcCtD
Ziprasidone—Dysuria—Lisinopril—dilated cardiomyopathy	0.00121	0.0028	CcSEcCtD
Ziprasidone—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.0012	0.00278	CcSEcCtD
Ziprasidone—Malnutrition—Furosemide—dilated cardiomyopathy	0.0012	0.00278	CcSEcCtD
Ziprasidone—Erythema—Furosemide—dilated cardiomyopathy	0.0012	0.00278	CcSEcCtD
Ziprasidone—Dizziness—Spironolactone—dilated cardiomyopathy	0.00119	0.00275	CcSEcCtD
Ziprasidone—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00119	0.00275	CcSEcCtD
Ziprasidone—ADRA2A—cardiac atrium—dilated cardiomyopathy	0.00119	0.00639	CbGeAlD
Ziprasidone—Flatulence—Furosemide—dilated cardiomyopathy	0.00118	0.00274	CcSEcCtD
Ziprasidone—HTR2A—heart—dilated cardiomyopathy	0.00118	0.00635	CbGeAlD
Ziprasidone—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00118	0.00273	CcSEcCtD
Ziprasidone—Weight increased—Lisinopril—dilated cardiomyopathy	0.00118	0.00272	CcSEcCtD
Ziprasidone—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00117	0.0027	CcSEcCtD
Ziprasidone—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00117	0.0027	CcSEcCtD
Ziprasidone—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00116	0.00268	CcSEcCtD
Ziprasidone—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00115	0.00267	CcSEcCtD
Ziprasidone—Vomiting—Spironolactone—dilated cardiomyopathy	0.00115	0.00265	CcSEcCtD
Ziprasidone—Rash—Spironolactone—dilated cardiomyopathy	0.00114	0.00263	CcSEcCtD
Ziprasidone—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00113	0.00262	CcSEcCtD
Ziprasidone—Renal failure—Lisinopril—dilated cardiomyopathy	0.00113	0.00262	CcSEcCtD
Ziprasidone—Vision blurred—Furosemide—dilated cardiomyopathy	0.00113	0.00262	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00113	0.00261	CcSEcCtD
Ziprasidone—Headache—Spironolactone—dilated cardiomyopathy	0.00113	0.00261	CcSEcCtD
Ziprasidone—Jaundice—Lisinopril—dilated cardiomyopathy	0.00112	0.0026	CcSEcCtD
Ziprasidone—Anaemia—Furosemide—dilated cardiomyopathy	0.00111	0.00257	CcSEcCtD
Ziprasidone—Sweating—Lisinopril—dilated cardiomyopathy	0.00111	0.00256	CcSEcCtD
Ziprasidone—Agitation—Furosemide—dilated cardiomyopathy	0.0011	0.00255	CcSEcCtD
Ziprasidone—Haematuria—Lisinopril—dilated cardiomyopathy	0.0011	0.00254	CcSEcCtD
Ziprasidone—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00109	0.00251	CcSEcCtD
Ziprasidone—Vertigo—Furosemide—dilated cardiomyopathy	0.00108	0.00249	CcSEcCtD
Ziprasidone—Leukopenia—Furosemide—dilated cardiomyopathy	0.00108	0.00248	CcSEcCtD
Ziprasidone—Nausea—Spironolactone—dilated cardiomyopathy	0.00107	0.00247	CcSEcCtD
Ziprasidone—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00105	0.00244	CcSEcCtD
Ziprasidone—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00104	0.0024	CcSEcCtD
Ziprasidone—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00104	0.00239	CcSEcCtD
Ziprasidone—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00103	0.00237	CcSEcCtD
Ziprasidone—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00102	0.00236	CcSEcCtD
Ziprasidone—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00102	0.00236	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00102	0.00235	CcSEcCtD
Ziprasidone—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00101	0.00235	CcSEcCtD
Ziprasidone—Dry mouth—Furosemide—dilated cardiomyopathy	0.001	0.00231	CcSEcCtD
Ziprasidone—Confusional state—Furosemide—dilated cardiomyopathy	0.000988	0.00228	CcSEcCtD
Ziprasidone—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000965	0.00223	CcSEcCtD
Ziprasidone—Shock—Furosemide—dilated cardiomyopathy	0.000964	0.00223	CcSEcCtD
Ziprasidone—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000961	0.00222	CcSEcCtD
Ziprasidone—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00096	0.00222	CcSEcCtD
Ziprasidone—Skin disorder—Furosemide—dilated cardiomyopathy	0.000952	0.0022	CcSEcCtD
Ziprasidone—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000948	0.00219	CcSEcCtD
Ziprasidone—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000939	0.00217	CcSEcCtD
Ziprasidone—Anorexia—Furosemide—dilated cardiomyopathy	0.000934	0.00216	CcSEcCtD
Ziprasidone—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000933	0.00216	CcSEcCtD
Ziprasidone—Chills—Lisinopril—dilated cardiomyopathy	0.000929	0.00215	CcSEcCtD
Ziprasidone—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.000925	0.00214	CcSEcCtD
Ziprasidone—Hypotension—Furosemide—dilated cardiomyopathy	0.000916	0.00212	CcSEcCtD
Ziprasidone—Alopecia—Lisinopril—dilated cardiomyopathy	0.000915	0.00211	CcSEcCtD
Ziprasidone—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000907	0.0021	CcSEcCtD
Ziprasidone—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000901	0.00208	CcSEcCtD
Ziprasidone—Erythema—Lisinopril—dilated cardiomyopathy	0.000901	0.00208	CcSEcCtD
Ziprasidone—Flatulence—Lisinopril—dilated cardiomyopathy	0.000888	0.00205	CcSEcCtD
Ziprasidone—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00088	0.00203	CcSEcCtD
Ziprasidone—Back pain—Lisinopril—dilated cardiomyopathy	0.000872	0.00201	CcSEcCtD
Ziprasidone—Somnolence—Furosemide—dilated cardiomyopathy	0.000871	0.00201	CcSEcCtD
Ziprasidone—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000866	0.002	CcSEcCtD
Ziprasidone—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000852	0.00197	CcSEcCtD
Ziprasidone—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000849	0.00196	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000846	0.00196	CcSEcCtD
Ziprasidone—Fatigue—Furosemide—dilated cardiomyopathy	0.000845	0.00195	CcSEcCtD
Ziprasidone—Tremor—Lisinopril—dilated cardiomyopathy	0.000844	0.00195	CcSEcCtD
Ziprasidone—Constipation—Furosemide—dilated cardiomyopathy	0.000838	0.00194	CcSEcCtD
Ziprasidone—Anaemia—Lisinopril—dilated cardiomyopathy	0.000833	0.00193	CcSEcCtD
Ziprasidone—Angioedema—Lisinopril—dilated cardiomyopathy	0.000823	0.0019	CcSEcCtD
Ziprasidone—Vertigo—Lisinopril—dilated cardiomyopathy	0.00081	0.00187	CcSEcCtD
Ziprasidone—Syncope—Lisinopril—dilated cardiomyopathy	0.000808	0.00187	CcSEcCtD
Ziprasidone—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000808	0.00187	CcSEcCtD
Ziprasidone—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000807	0.00186	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000802	0.00185	CcSEcCtD
Ziprasidone—Palpitations—Lisinopril—dilated cardiomyopathy	0.000796	0.00184	CcSEcCtD
Ziprasidone—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000792	0.00183	CcSEcCtD
Ziprasidone—Cough—Lisinopril—dilated cardiomyopathy	0.000786	0.00182	CcSEcCtD
Ziprasidone—Urticaria—Furosemide—dilated cardiomyopathy	0.000779	0.0018	CcSEcCtD
Ziprasidone—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000775	0.00179	CcSEcCtD
Ziprasidone—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000775	0.00179	CcSEcCtD
Ziprasidone—Myalgia—Lisinopril—dilated cardiomyopathy	0.000767	0.00177	CcSEcCtD
Ziprasidone—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000767	0.00177	CcSEcCtD
Ziprasidone—Chest pain—Lisinopril—dilated cardiomyopathy	0.000767	0.00177	CcSEcCtD
Ziprasidone—Anxiety—Lisinopril—dilated cardiomyopathy	0.000765	0.00177	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000762	0.00176	CcSEcCtD
Ziprasidone—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00075	0.00173	CcSEcCtD
Ziprasidone—Confusional state—Lisinopril—dilated cardiomyopathy	0.000742	0.00171	CcSEcCtD
Ziprasidone—Infection—Lisinopril—dilated cardiomyopathy	0.000731	0.00169	CcSEcCtD
Ziprasidone—Shock—Lisinopril—dilated cardiomyopathy	0.000724	0.00167	CcSEcCtD
Ziprasidone—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000722	0.00167	CcSEcCtD
Ziprasidone—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00072	0.00166	CcSEcCtD
Ziprasidone—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000718	0.00166	CcSEcCtD
Ziprasidone—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000714	0.00165	CcSEcCtD
Ziprasidone—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000711	0.00164	CcSEcCtD
Ziprasidone—Asthenia—Furosemide—dilated cardiomyopathy	0.000703	0.00163	CcSEcCtD
Ziprasidone—Anorexia—Lisinopril—dilated cardiomyopathy	0.000701	0.00162	CcSEcCtD
Ziprasidone—Hypotension—Lisinopril—dilated cardiomyopathy	0.000687	0.00159	CcSEcCtD
Ziprasidone—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000671	0.00155	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00067	0.00155	CcSEcCtD
Ziprasidone—Insomnia—Lisinopril—dilated cardiomyopathy	0.000665	0.00154	CcSEcCtD
Ziprasidone—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00066	0.00153	CcSEcCtD
Ziprasidone—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000656	0.00152	CcSEcCtD
Ziprasidone—Somnolence—Lisinopril—dilated cardiomyopathy	0.000654	0.00151	CcSEcCtD
Ziprasidone—Dizziness—Furosemide—dilated cardiomyopathy	0.000648	0.0015	CcSEcCtD
Ziprasidone—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000647	0.0015	CcSEcCtD
Ziprasidone—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000639	0.00148	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000635	0.00147	CcSEcCtD
Ziprasidone—Fatigue—Lisinopril—dilated cardiomyopathy	0.000634	0.00147	CcSEcCtD
Ziprasidone—Constipation—Lisinopril—dilated cardiomyopathy	0.000629	0.00145	CcSEcCtD
Ziprasidone—Vomiting—Furosemide—dilated cardiomyopathy	0.000623	0.00144	CcSEcCtD
Ziprasidone—Rash—Furosemide—dilated cardiomyopathy	0.000618	0.00143	CcSEcCtD
Ziprasidone—Dermatitis—Furosemide—dilated cardiomyopathy	0.000617	0.00143	CcSEcCtD
Ziprasidone—Headache—Furosemide—dilated cardiomyopathy	0.000614	0.00142	CcSEcCtD
Ziprasidone—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000606	0.0014	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000601	0.00139	CcSEcCtD
Ziprasidone—Urticaria—Lisinopril—dilated cardiomyopathy	0.000584	0.00135	CcSEcCtD
Ziprasidone—Nausea—Furosemide—dilated cardiomyopathy	0.000582	0.00135	CcSEcCtD
Ziprasidone—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000581	0.00134	CcSEcCtD
Ziprasidone—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000581	0.00134	CcSEcCtD
Ziprasidone—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000542	0.00125	CcSEcCtD
Ziprasidone—Asthenia—Lisinopril—dilated cardiomyopathy	0.000528	0.00122	CcSEcCtD
Ziprasidone—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000503	0.00116	CcSEcCtD
Ziprasidone—Dizziness—Lisinopril—dilated cardiomyopathy	0.000486	0.00112	CcSEcCtD
Ziprasidone—Vomiting—Lisinopril—dilated cardiomyopathy	0.000468	0.00108	CcSEcCtD
Ziprasidone—Rash—Lisinopril—dilated cardiomyopathy	0.000464	0.00107	CcSEcCtD
Ziprasidone—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000463	0.00107	CcSEcCtD
Ziprasidone—Headache—Lisinopril—dilated cardiomyopathy	0.000461	0.00106	CcSEcCtD
Ziprasidone—Nausea—Lisinopril—dilated cardiomyopathy	0.000437	0.00101	CcSEcCtD
Ziprasidone—CHRM2—Signaling Pathways—CXCL2—dilated cardiomyopathy	3.82e-05	0.000101	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—AGTR2—dilated cardiomyopathy	3.82e-05	0.000101	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.81e-05	0.0001	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.81e-05	0.0001	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	3.81e-05	0.0001	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	3.81e-05	0.0001	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—RAC1—dilated cardiomyopathy	3.79e-05	9.98e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.78e-05	9.96e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.77e-05	9.92e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.76e-05	9.89e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	3.74e-05	9.83e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—RAC1—dilated cardiomyopathy	3.73e-05	9.82e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—RAC1—dilated cardiomyopathy	3.72e-05	9.8e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—RAC1—dilated cardiomyopathy	3.71e-05	9.76e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.71e-05	9.75e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—RAC1—dilated cardiomyopathy	3.7e-05	9.73e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.7e-05	9.73e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.68e-05	9.67e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—RAC1—dilated cardiomyopathy	3.66e-05	9.64e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—RAC1—dilated cardiomyopathy	3.65e-05	9.61e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.65e-05	9.6e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.65e-05	9.6e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—AGT—dilated cardiomyopathy	3.62e-05	9.53e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.62e-05	9.52e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.61e-05	9.5e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.6e-05	9.47e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.6e-05	9.47e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.59e-05	9.44e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.59e-05	9.44e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—GPCR downstream signaling—AGT—dilated cardiomyopathy	3.57e-05	9.4e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—AGT—dilated cardiomyopathy	3.56e-05	9.38e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.56e-05	9.37e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—AGT—dilated cardiomyopathy	3.56e-05	9.36e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.55e-05	9.35e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—AGT—dilated cardiomyopathy	3.54e-05	9.33e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.54e-05	9.32e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—AGTR2—dilated cardiomyopathy	3.54e-05	9.32e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CXCL2—dilated cardiomyopathy	3.54e-05	9.32e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—AGT—dilated cardiomyopathy	3.53e-05	9.3e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.5e-05	9.22e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—AGT—dilated cardiomyopathy	3.5e-05	9.21e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.49e-05	9.2e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.49e-05	9.2e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—AGT—dilated cardiomyopathy	3.49e-05	9.18e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.48e-05	9.17e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.47e-05	9.14e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.46e-05	9.11e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—RAC1—dilated cardiomyopathy	3.44e-05	9.07e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.44e-05	9.07e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.44e-05	9.07e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—RAC1—dilated cardiomyopathy	3.44e-05	9.06e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.44e-05	9.05e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.44e-05	9.04e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.43e-05	9.03e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—RAC1—dilated cardiomyopathy	3.42e-05	9e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.4e-05	8.96e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—RAC1—dilated cardiomyopathy	3.39e-05	8.93e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.35e-05	8.82e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—RAC1—dilated cardiomyopathy	3.35e-05	8.81e-05	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—RAF1—dilated cardiomyopathy	3.34e-05	8.8e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.33e-05	8.76e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—GPX1—dilated cardiomyopathy	3.31e-05	8.72e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.3e-05	8.68e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—RAC1—dilated cardiomyopathy	3.29e-05	8.67e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—AGT—dilated cardiomyopathy	3.29e-05	8.66e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.29e-05	8.66e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—AGT—dilated cardiomyopathy	3.29e-05	8.65e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.28e-05	8.65e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.28e-05	8.65e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.28e-05	8.64e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.27e-05	8.6e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—AGT—dilated cardiomyopathy	3.27e-05	8.6e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—RAC1—dilated cardiomyopathy	3.25e-05	8.55e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—AGT—dilated cardiomyopathy	3.24e-05	8.53e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.24e-05	8.53e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	3.24e-05	8.52e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—CD36—dilated cardiomyopathy	3.22e-05	8.49e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—GPX1—dilated cardiomyopathy	3.22e-05	8.46e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—AGT—dilated cardiomyopathy	3.2e-05	8.42e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.19e-05	8.39e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.18e-05	8.37e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	3.15e-05	8.3e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—AGT—dilated cardiomyopathy	3.15e-05	8.28e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—CD36—dilated cardiomyopathy	3.13e-05	8.24e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.13e-05	8.23e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—RAC1—dilated cardiomyopathy	3.11e-05	8.19e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—AGT—dilated cardiomyopathy	3.1e-05	8.17e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.04e-05	8e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.99e-05	7.87e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.98e-05	7.86e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.98e-05	7.83e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—AGT—dilated cardiomyopathy	2.97e-05	7.83e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.97e-05	7.81e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.97e-05	7.81e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.97e-05	7.81e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—RAF1—dilated cardiomyopathy	2.96e-05	7.79e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.94e-05	7.73e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.93e-05	7.71e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—RAC1—dilated cardiomyopathy	2.93e-05	7.7e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.92e-05	7.7e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—AGT—dilated cardiomyopathy	2.9e-05	7.64e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.88e-05	7.59e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.86e-05	7.53e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.85e-05	7.5e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—GPX1—dilated cardiomyopathy	2.85e-05	7.49e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.84e-05	7.47e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.84e-05	7.47e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—AGT—dilated cardiomyopathy	2.83e-05	7.46e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.83e-05	7.45e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.82e-05	7.43e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.82e-05	7.43e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—AGT—dilated cardiomyopathy	2.82e-05	7.42e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.81e-05	7.41e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.81e-05	7.39e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—AGT—dilated cardiomyopathy	2.8e-05	7.36e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.79e-05	7.33e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.78e-05	7.31e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—CD36—dilated cardiomyopathy	2.77e-05	7.3e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.77e-05	7.29e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.73e-05	7.19e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.73e-05	7.18e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.72e-05	7.16e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.69e-05	7.08e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.65e-05	6.98e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.65e-05	6.97e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—RAC1—dilated cardiomyopathy	2.64e-05	6.95e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.63e-05	6.93e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—GPX1—dilated cardiomyopathy	2.61e-05	6.88e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.58e-05	6.8e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.58e-05	6.78e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—RAC1—dilated cardiomyopathy	2.55e-05	6.71e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—CD36—dilated cardiomyopathy	2.54e-05	6.7e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—RAC1—dilated cardiomyopathy	2.54e-05	6.68e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.54e-05	6.67e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—AGT—dilated cardiomyopathy	2.52e-05	6.64e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.51e-05	6.62e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.5e-05	6.58e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—AGT—dilated cardiomyopathy	2.5e-05	6.57e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.48e-05	6.52e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.47e-05	6.51e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—RAC1—dilated cardiomyopathy	2.47e-05	6.5e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.47e-05	6.5e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.46e-05	6.47e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.45e-05	6.45e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.44e-05	6.42e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—AGT—dilated cardiomyopathy	2.44e-05	6.41e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.43e-05	6.4e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—RAC1—dilated cardiomyopathy	2.43e-05	6.39e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.43e-05	6.39e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.43e-05	6.38e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—AGT—dilated cardiomyopathy	2.42e-05	6.38e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.42e-05	6.37e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.42e-05	6.36e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.4e-05	6.31e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.39e-05	6.3e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	2.39e-05	6.3e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.39e-05	6.28e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—AGT—dilated cardiomyopathy	2.36e-05	6.21e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	2.33e-05	6.14e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—AGT—dilated cardiomyopathy	2.32e-05	6.11e-05	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—EGFR—dilated cardiomyopathy	2.29e-05	6.04e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—AGT—dilated cardiomyopathy	2.29e-05	6.03e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—RAF1—dilated cardiomyopathy	2.28e-05	6.01e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.28e-05	6.01e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—RAF1—dilated cardiomyopathy	2.28e-05	6.01e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—RAF1—dilated cardiomyopathy	2.27e-05	5.97e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.25e-05	5.93e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.25e-05	5.92e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—RAC1—dilated cardiomyopathy	2.24e-05	5.89e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—RAF1—dilated cardiomyopathy	2.22e-05	5.84e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.22e-05	5.84e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—RAC1—dilated cardiomyopathy	2.2e-05	5.8e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.2e-05	5.79e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.19e-05	5.77e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—RAF1—dilated cardiomyopathy	2.18e-05	5.75e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—RAC1—dilated cardiomyopathy	2.18e-05	5.75e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—RAC1—dilated cardiomyopathy	2.16e-05	5.69e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—RAC1—dilated cardiomyopathy	2.16e-05	5.68e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—RAF1—dilated cardiomyopathy	2.15e-05	5.67e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—AGT—dilated cardiomyopathy	2.14e-05	5.63e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—AGT—dilated cardiomyopathy	2.1e-05	5.54e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—AGT—dilated cardiomyopathy	2.1e-05	5.53e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	2.1e-05	5.52e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—AGT—dilated cardiomyopathy	2.09e-05	5.51e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—AGT—dilated cardiomyopathy	2.09e-05	5.49e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—AGT—dilated cardiomyopathy	2.07e-05	5.44e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—RAF1—dilated cardiomyopathy	2.06e-05	5.43e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—AGT—dilated cardiomyopathy	2.06e-05	5.43e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.03e-05	5.35e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—EGFR—dilated cardiomyopathy	2.03e-05	5.34e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—RAC1—dilated cardiomyopathy	2e-05	5.28e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.97e-05	5.18e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.96e-05	5.17e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.95e-05	5.14e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—RAF1—dilated cardiomyopathy	1.94e-05	5.11e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—AGT—dilated cardiomyopathy	1.91e-05	5.04e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.9e-05	5e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.87e-05	4.92e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—RAF1—dilated cardiomyopathy	1.75e-05	4.61e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.72e-05	4.54e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	1.7e-05	4.48e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.7e-05	4.46e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.69e-05	4.45e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—RAF1—dilated cardiomyopathy	1.69e-05	4.45e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.69e-05	4.44e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—RAF1—dilated cardiomyopathy	1.68e-05	4.43e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.68e-05	4.43e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.66e-05	4.38e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.66e-05	4.37e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	1.66e-05	4.36e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—RAF1—dilated cardiomyopathy	1.64e-05	4.31e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—RAF1—dilated cardiomyopathy	1.61e-05	4.24e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—EGFR—dilated cardiomyopathy	1.57e-05	4.12e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—EGFR—dilated cardiomyopathy	1.56e-05	4.12e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—EGFR—dilated cardiomyopathy	1.55e-05	4.09e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.54e-05	4.06e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—EGFR—dilated cardiomyopathy	1.52e-05	4.01e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—EGFR—dilated cardiomyopathy	1.5e-05	3.94e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	1.49e-05	3.93e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—RAF1—dilated cardiomyopathy	1.48e-05	3.91e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—EGFR—dilated cardiomyopathy	1.48e-05	3.89e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—RAF1—dilated cardiomyopathy	1.46e-05	3.85e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.46e-05	3.84e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.45e-05	3.82e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—RAF1—dilated cardiomyopathy	1.45e-05	3.81e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	1.44e-05	3.8e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—RAF1—dilated cardiomyopathy	1.43e-05	3.78e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—RAF1—dilated cardiomyopathy	1.43e-05	3.77e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—EGFR—dilated cardiomyopathy	1.42e-05	3.72e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	1.4e-05	3.7e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.35e-05	3.55e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—EGFR—dilated cardiomyopathy	1.33e-05	3.5e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—RAF1—dilated cardiomyopathy	1.33e-05	3.5e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	1.26e-05	3.33e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—EGFR—dilated cardiomyopathy	1.2e-05	3.16e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—EGFR—dilated cardiomyopathy	1.16e-05	3.05e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—EGFR—dilated cardiomyopathy	1.15e-05	3.04e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—EGFR—dilated cardiomyopathy	1.12e-05	2.95e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	1.11e-05	2.93e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—EGFR—dilated cardiomyopathy	1.1e-05	2.91e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	1.08e-05	2.85e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—EGFR—dilated cardiomyopathy	1.02e-05	2.68e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—EGFR—dilated cardiomyopathy	1e-05	2.64e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—EGFR—dilated cardiomyopathy	1e-05	2.63e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—EGFR—dilated cardiomyopathy	9.96e-06	2.62e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—EGFR—dilated cardiomyopathy	9.93e-06	2.61e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—EGFR—dilated cardiomyopathy	9.84e-06	2.59e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—EGFR—dilated cardiomyopathy	9.81e-06	2.58e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	9.76e-06	2.57e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—EGFR—dilated cardiomyopathy	9.11e-06	2.4e-05	CbGpPWpGaD
